Leerink Partnrs Has Negative Estimate for KROS Q3 Earnings

Key Points

• Leerink Partners has revised down its Q3 2025 earnings estimate for Keros Therapeutics, projecting an earning of ($0.87) per share, down from ($0.82).
• The consensus estimate for Keros Therapeutics' full-year earnings stands at ($4.74) per share, with several analysts adjusting their price targets for the stock.
• Keros Therapeutics reported a quarterly EPS of ($0.76), which surpassed the consensus estimate of ($1.14).

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at Leerink Partnrs reduced their Q3 2025 earnings estimates for Keros Therapeutics in a note issued to investors on Thursday, August 7th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.87) per share for the quarter, down from their prior forecast of ($0.82). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at $1.25 EPS, FY2026 earnings at ($4.26) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($1.08) EPS and FY2029 earnings at ($1.59) EPS.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, beating analysts' consensus estimates of ($1.14) by $0.38. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The company's revenue for the quarter was up 49002.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.25) earnings per share.

A number of other research firms also recently weighed in on KROS. Wedbush reissued a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research note on Friday, May 30th. Scotiabank dropped their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday, May 12th. HC Wainwright dropped their price target on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Bank of America downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $32.00 to $18.00 in a research note on Tuesday, June 10th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $30.00.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded up $0.32 during trading on Monday, reaching $14.28. The company had a trading volume of 109,065 shares, compared to its average volume of 990,366. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37. The stock has a market cap of $580.05 million, a PE ratio of 45.90, a PEG ratio of 1.68 and a beta of 1.33. The business's 50 day moving average price is $13.96 and its 200-day moving average price is $12.82.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of KROS. Vanguard Group Inc. boosted its holdings in shares of Keros Therapeutics by 5.4% in the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock valued at $30,981,000 after buying an additional 100,691 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Keros Therapeutics by 585.9% in the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock valued at $3,379,000 after buying an additional 182,314 shares during the period. Norges Bank acquired a new position in shares of Keros Therapeutics in the fourth quarter valued at approximately $1,027,000. Geode Capital Management LLC boosted its holdings in shares of Keros Therapeutics by 5.5% in the fourth quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after buying an additional 39,815 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in shares of Keros Therapeutics by 37.6% in the fourth quarter. Wells Fargo & Company MN now owns 15,208 shares of the company's stock valued at $241,000 after buying an additional 4,153 shares during the period. Institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.